^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO Asia 2023
    Title:

    63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer

    Published date:
    11/27/2023
    Excerpt:
    In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile.